# Major strides are being made in the health sector, with C4 Therapeutics linking up with Roche for a cancer drug development deal that could exceed $1 billion.

*business · news · 2026-04-10 · Devdiscourse*

## Key points

- C4 Therapeutics and Roche have partnered on degrader-antibody conjugates for undisclosed cancer targets.
- The C4 Therapeutics-Roche deal could exceed $1 billion in value.
- AG1 is exploring strategic options and may be valued at over $2 billion.
- 23AndMe research links GLP1R gene variations to individual responses to GLP-1 obesity drugs.

**Companies:** Roche, C4 Therapeutics, AG1, 23AndMe

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3870006-major-health-developments-from-cancer-deals-to-gene-linked-weight-loss-insights)

---

Canonical: https://newsio.io/n/54013746-9faf-4a8a-a5dc-45eff8cd9afe/major-strides-are-being-made-in-the-health-sector-with-c4-therapeutics-linking-u
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works